Status:
NOT_YET_RECRUITING
Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.
Detailed Description
Primary Objective: Assess the feasibility of delivering the ACLP, ACLP-LC, and ACLP-LC-IHC programs in stable HR+/HER2- MBC survivors. Feasibility criteria will include the percent of eligible patien...
Eligibility Criteria
Inclusion
- Patients with HR+/HER2 negative MBC
- On first- or second-line treatment
- Life expectancy at least 12 months
- Only females
- Age 18 years or older
- Able to read, write, and speak English
- Willingness to follow protocol requirements
- Have a smartphone with access to cellular service or computer access with internet service
- Oriented to person, place, and time
- Consume less than 3 servings of fruit and vegetable/day
- Engage in less than 150 minutes moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling)
- Engage in a mind-body practice less than 4 times a month
Exclusion
- Another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers)
- Any major thought disorder (e.g., schizophrenia, dementia)
- Communication barriers (e.g., hard of hearing)
- Poorly-controlled or uncontrolled diabetes in the opinion of the physician(s)
- Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)
Key Trial Info
Start Date :
February 28 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07179809
Start Date
February 28 2026
End Date
October 1 2029
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030